Fine-tuned manipulation of the c-MET oncogenic pathway in pancreatic cancer: a new paradigm of personalised medicine.

点击翻译按钮获取中文摘要

Only 8% of patients with pancreatic cancer (PC) survive the disease, and current therapies, tested in all-comers, have limited success. More than a third of patients with PC may benefit from a novel combination therapy of agents that target cancer cell growth and survival. Significance of our work lies in identifying treatment strategies that can be directed to PC patients in a subgroup-selective manner, ultimately leading to reductions in the mortality associated with this lethal cancer.